Loading clinical trials...
Loading clinical trials...
Compare the Renal Protective Effects of Febuxostat and Benzbromarone in Chronic Kidney Disease Patients With GFR 20-50ml/Min
The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function, and which one could be better.
Chronic kidney disease patients with hyperuricemia and glomerular filtration rate (GFR) 20-50 ml/min were treated by febuxostat or benzbromarone. Follow up the changes of serum uric acid, serum creatinine and GFR levels. Compare the effects on renal function of these two drugs.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China
Start Date
January 1, 2015
Primary Completion Date
December 1, 2018
Completion Date
December 1, 2018
Last Updated
July 24, 2019
160
ACTUAL participants
Febuxostat
DRUG
Benzbromarone
DRUG
Lead Sponsor
Shanghai 10th People's Hospital
NCT07241390
NCT06926660
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06717698